Background and Objectives: In this study, we describe our first experiences with the new method of transvesical suprapubic externalization of ureteral stents. This method is assessed in patients with incurable ureteral obstruction and concomitant bladder dysfunction, and is classified according to the Idea, Development, Exploration, Assessment, Long-Term Study (IDEAL) recommendations. Patients and Methods: From 2009 to 2015, transvesical suprapubic externalization of ureteral stents was applied in 14 (8 males, 6 females) patients with incurable ureteral obstruction of malignant (n = 9, 64%) or benign (n = 5; 36%) etiology. All the patients had concomitant bladder pathologies that impaired quality of life (QoL). Classification according to IDEAL followed the respective recommendations. Results: Only minor complications, except 1 major complication not directly related to the procedure, were observed. QoL improvement was reported in all patients. The duration for this surgery was 45 (17-86) min; however, it varied between genders (female 37 min, male 51 min). The mean follow-up period was 26.6 months ranging from 12 to 73 months. Transvesical suprapubic externalization of ureteral stents resulted in a stable renal function and the elimination of urinary leakage via a compromised bladder in all patients. Conclusions: Transvesical externalization of ureteral stents is a feasible method for urinary diversion, which seems to improve patients' QoL in appropriate indications. The method can be classified as IDEAL stage 2a.

Keywords:
Idea, Development, Exploration, Assessment, Long-Term Study, Surgical innovation, Ureteral stent, Urinary diversion, IDEAL
1.
McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, et al: No surgical innovation without evaluation: the IDEAL recommendations. Lancet 2009;374:1105-1112.
2.
McCulloch P: The IDEAL recommendations and urological innovation. World J Urol 2011;29:331-336.
3.
Gerullis H, Klosterhalfen B, Boros M, Lammers B, Eimer C, Georgas E, et al: IDEAL in meshes for prolapse, urinary incontinence, and hernia repair. Surg Innov 2013;20:502-508.
4.
Saglam R, Muslumanoglu AY, Tokatli Z, Caskurlu T, Sarica K, Tasci AI, et al: A new robot for flexible ureteroscopy: development and early clinical results (IDEAL stage 1-2b). Eur Urol 2014;66:1092-1100.
5.
Menon M, Sood A, Bhandari M, Kher V, Ghosh P, Abaza R, et al: Robotic kidney transplantation with regional hypothermia: a step-by-step description of the Vattikuti Urology Institute-Medanta technique (IDEAL phase 2a). Eur Urol 2014;65:991-1000.
6.
Grabstald H, McPhee M: Nephrostomy and the cancer patient. South Med J 1973;66:217-220.
7.
Gerullis H, Ecke TH, Schwartmann K, Heuck CJ, Eimer C, Bagner JW, et al: Nephrocutaneous bypass in ureteral obstruction. Urology 2010;76:480-485.
8.
McCulloch P, Cook JA, Altman DG, Heneghan C, Diener MK; IDEAL Group: IDEAL framework for surgical innovation 1: the idea and development stages. BMJ 2013;346:f3012.
9.
Eimer C, Gerullis H, Schwartmann K, El Baz A, Otto T: Synchronous arterioureteral, ureterocolic and arteriocolic fistula in a patient with metastasised carcinoid tumor - an upcoming problem for long-term survivors of anticancer therapy. Curr Urol 2008;2:110-112.
10.
Gheiler EL, Tefilli MV, Tiguert R, Friedland MS, Frontera RC, Pontes JE: Angiographic arterial occlusion and extra-anatomical vascular bypass for the management of a ureteral-iliac fistula: case report and review of the literature. Urol Int 1998;61:62-66.
11.
Jones CR, Woodhouse CR, Hendry WF: Urological problems following treatment of carcinoma of the cervix. Br J Urol 1984;56:609-613.
12.
Lee MY, Wu HG, Kim K, Ha SW, Kim JS, Kim IA, et al: Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2007;104:95-99.
13.
Moore KN, Gold MA, McMeekin DS, Zorn KK: Vesicovaginal fistula formation in patients with stage IVA cervical carcinoma. Gynecol Oncol 2007;106:498-501.
14.
Zhou L, Yang TX, Luo DY, Chen SL, Liao BH, Li H, et al: Factors influencing repair outcomes of vesicovaginal fistula: a retrospective review of 139 procedures. Urol Int 2016, Epub ahead of print.
15.
Woodhouse CR: Supra-vesical urinary diversion and ureteric re-implantation for malignant disease. Clin Oncol (R Coll Radiol) 2010;22:727-732.
16.
Shekarriz B, Shekarriz H, Upadhyay J, Banerjee M, Becker H, Pontes JE, et al: Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer 1999;85:998-1003.
17.
Fallon B, Olney L, Culp DA: Nephrostomy in cancer patients: to do or not to do? Br J Urol 1980;52:237-242.
18.
Blazeby JM, Blencowe NS, Titcomb DR, Metcalfe C, Hollowood AD, Barham CP: Demonstration of the IDEAL recommendations for evaluating and reporting surgical innovation in minimally invasive oesophagectomy. Br J Surg 2011;98:544-551.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.